Evidence map›Paper›PMID 29523664›Full record

ArticleJournal of the National Comprehensive Cancer Network : JNCCN2018

Clinical and Genetic Risk Factors for Adverse Metabolic Outcomes in North American Testicular Cancer Survivors.

Mohammad Abu Zaid, Wambui G Gathirua-Mwangi, Chunkit Fung, Patrick O Monahan, Omar El-Charif, Annalynn M Williams, Darren R Feldman, Robert J Hamilton, David J Vaughn, Clair J Beard and 9 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of the National Comprehensive Cancer Network : JNCCN, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. SEOM-GG clinical guidelines for the management of germ-cell testicular cancer (2023).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Guideline
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Review
  7. Article
  8. Review
  9. Testicular cancer survivorship: Long-term toxicity and management.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2022
    Review
  10. Article
  11. Article
  12. Review
  13. Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020
    Article
  14. Article
  15. Article
  16. Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019
    Article
  17. Article
  18. Testicular cancer.Nature reviews. Disease primers · 2018
    Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 11 institutions in 4 countries.

Mohammad Abu Zaid
Wambui G Gathirua-Mwangi
Chunkit Fung
Patrick O Monahan
Omar El-Charif
Annalynn M Williams
Darren R Feldman
Robert J Hamilton
David J Vaughn
Clair J Beard
Ryan Cook
Sandra K Althouse
Shirin Ardeshir-Rouhani-Fard
Paul C Dinh
Howard D Sesso
Lawrence H Einhorn
Sophie D Fossa
Lois B Travis
Platinum Study Group
Indiana University Health · USIndiana University – Purdue University Indianapolis · USIndiana University · USUniversity of Rochester Medical Center · USDana-Farber Cancer Institute · USGeneral Department of Preventive Medicine · VNMemorial Sloan Kettering Cancer Center · USOslo University Hospital · NOPrincess Margaret Cancer Centre · CAUniversity of Chicago · USUniversity of Pennsylvania · US

Funding

URCC NCORP Research BaseUG1CA189961 · NCI · UNIVERSITY OF ROCHESTER · PI Michelle C Janelsins, KAREN M. MUSTIAN · 2014 to 2026
$67.7M
Genetic Susceptibility and Biomarkers of Platinum-related ToxicitiesR01CA157823 · NCI · UNIVERSITY OF ROCHESTER · PI TRAVIS, LOIS B. · 2012 to 2025
$11.2M
Cancer Control Research Training Curriculum (R25T)R25CA102618 · NCI · UNIVERSITY OF ROCHESTER · PI JANELSINS, MICHELLE C, MORROW, GARY R · 2004 to 2018
$6.7M
Comparative Effectiveness of Interventions to Improve Screening Among Rural WomenR01CA196243 · NCI · OHIO STATE UNIVERSITY · PI CHAMPION, VICTORIA LEE, PASKETT, ELECTRA D. · 2015 to 2019
$3.4M
Research and Training for Behavioral Oncology InterventionsK05CA175048 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI CHAMPION, VICTORIA LEE · 2014 to 2018
$484k
NCI NIH HHS K05 CA175048NCI NIH HHS R01 CA157823NCI NIH HHS R01 CA196243NCI NIH HHS R25 CA102618NCI NIH HHS UG1 CA189961
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Cancer SurvivorsAdultBiomarkersCase-Control StudiesComorbidityGenetic VariationHumansMaleMiddle AgedNeoplasms, Germ Cell and EmbryonalPrevalencePrognosisRisk FactorsSocioeconomic FactorsTesticular NeoplasmsYoung AdultBiomarkers

Identifiers

PMID29523664
PMCPMC6345519
OpenAlexW2789505351

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.